Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study
Bewertung der Wirksamkeit von Romiplostim bei der Behandlung von chemotherapieinduzierter Thrombozytopenie bei indischen Patient:innen: retrospektive Studie
South Asian Journal of Cancer · 01.07.2025 · 14 (03) · 597-600
DOI: 10.1055/s-0045-1809351 ↗Auf einen Blick
Bei 100 Patient:innen mit chemotherapieinduzierter Thrombozytopenie erhöhte Romiplostim die Thrombozytenzahlen in allen Gruppen signifikant. Die Studie berichtet eine Wirksamkeit unabhängig vom Schweregrad.
Fragestellung
Wie wirksam und sicher ist Romiplostim bei Patient:innen mit chemotherapieinduzierter Thrombozytopenie in einem Real-World-Setting?
Methode
Retrospektive, monozentrische Studie bei Patient:innen mit soliden Tumoren oder hämatologischen Malignomen und persistierender Thrombozytopenie, die Romiplostim erhielten.
Ergebnisse
100 Patient:innen: Romiplostim 500 mcg (N = 56), Romiplostim 500 mcg + 1-unit RDP (N = 35), Romiplostim 500 mcg + 2-unit RDP (N = 9). Thrombozyten stiegen in allen Gruppen signifikant (p < 0,001).
Schlussfolgerung der Autor:innen
Romiplostim war wirksam zur Erhöhung der Thrombozytenzahlen bei CIT unabhängig vom Thrombozytopeniegrad.
Kernaussagen
- 100 Patient:innen mit CIT wurden retrospektiv ausgewertet
- Romiplostim erhöhte die Thrombozytenzahlen in allen Gruppen
- Wirksamkeit wurde bei allen Schweregraden berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift South Asian Journal of Cancer, erschienen am 01.07.2025. Verfasst von Vikas Talreja und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Regency Hospital Ltd, Kanpur, Uttar Pradesh, India. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication of antineoplastic therapy. The incidence of CIT varies with cancer type and regimen used. CIT can result in chemotherapy delays, dose reductions, and discontinuation, leading to reduced survival rates· Romiplostim is a thrombopoietin receptor agonist that is effective for the treatment of CIT. This article evaluates the efficacy and safety of romiplostim in patients with CIT in a real-world setting The study was a retrospective, single-center study, which enrolled patients with solid tumors or hematological malignancies with persistent thrombocytopenia who had been treated with romiplostim. A total of 100 patients with CIT were categorized into three treatment groups: romiplostim 500 mcg (N = 56), romiplostim 500 mcg + 1-unit random donor platelets (RDP) (N = 35), and romiplostim 500 mcg + 2-unit RDP (N = 9). The most common malignancies were gallbladder carcinoma in the romiplostim 500 mcg group, breast cancer in the romiplostim 500 mcg + 1-unit RDP group (31.4%), and gallbladder and head and neck carcinoma in the romiplostim 500 mcg + 2-unit RDP group. Chemotherapy regimens varied, with gemcitabine + cisplatin (26.7%), Adriamycin + cyclophosphamide (31%), and paclitaxel + carboplatin (22%) being the most used in each group, respectively. Grade I thrombocytopenia was most frequent with Capox (22.2%), grade II with gemcitabine + cisplatin (42.3%), grade III with paclitaxel + carboplatin and gemcitabine + cisplatin (17.02%), and grade IV with paclitaxel + carboplatin (44.4%). Romiplostim significantly increased platelet counts across all groups (p < 0.001), demonstrating its effectiveness in managing CIT across all severity grades. Romiplostim was effective in increasing platelet counts regardless of the grade of thrombocytopenia. Romiplostim use for the management of CIT will help in correcting CIT and allow resumption of chemotherapy without recurrence of CIT in most patients undergoing cancer chemotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Regency Hospital Ltd, Kanpur, Uttar Pradesh, India.
- Department of Pediatrics, Rama Hospital and University, Kanpur, Uttar Pradesh, India.
- Department of Medical Affairs, Alkem Laboratories Ltd, Mumbai, Maharashtra, India.
ORCID-Profile: Vikas Talreja
Zitieren
APA
Talreja, V., Khatwani, S., & Subhagan, P. (2025). Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study. South Asian Journal of Cancer, 14(03), 597-600. https://doi.org/10.1055/s-0045-1809351
Vancouver
Talreja V, Khatwani S, Subhagan P. Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study. South Asian Journal of Cancer. 2025;14(03):597-600. doi:10.1055/s-0045-1809351
BibTeX
@article{Talreja2025,
author = {Talreja, Vikas and Khatwani, Sangeeta and Subhagan, Priyanka},
title = {Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study},
journal = {South Asian Journal of Cancer},
year = {2025},
volume = {14},
number = {03},
pages = {597--600},
doi = {10.1055/s-0045-1809351}
}
EUVIMED